Literature DB >> 18006836

Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.

Franck Meslin1, Ahmed Hamaï, Ping Gao, Abdelali Jalil, Nathalie Cahuzac, Salem Chouaib, Maryam Mehrpour.   

Abstract

We investigated the relationship between the resistance to the proapoptotic action of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and cellular prion protein (PrPc) function, using the TRAIL-sensitive MCF-7 human breast adenocarcinoma cell line and two TRAIL-resistant sublines: 2101 and MCF-7/ADR. All of the cell lines tested expressed TRAIL-R1 and TRAIL-R2. TRAIL decoy receptors were not detected, suggesting that the resistance of 2101 and MCF-7/ADR cells, strongly expressing PrPc, to TRAIL-mediated cell death was independent from the expression of TRAIL receptors and death-inducing signaling complex formation. Down-regulation of PrPc by small interfering RNA increased the sensitivity of Adriamycin- and TRAIL-resistant cells to TRAIL, but not to epirubicin/Adriamycin. TRAIL-mediated apoptosis in PrPc knocked-down cells was associated with caspase processing, Bid cleavage, and Mcl-1 degradation. In addition, an increased sensitivity of apoptosis-resistant cells to TRAIL after PrPc silencing was not associated with the increased recruitment of receptors and intracellular signaling molecule to the death-inducing signaling complex. Bcl-2 expression was substantially decreased after PrPc knock-down but the levels of Bcl-X(L) and Mcl-1 were not affected. The down-regulation of Bcl-2 was concomitant with Bax delocalization. Our findings support the notion that silencing of PrPc facilitates the activation of proapoptotic Bax by down-regulation of Bcl-2 expression, thereby abolishing the resistance of breast cancer cells to TRAIL-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006836     DOI: 10.1158/0008-5472.CAN-07-0512

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance.

Authors:  Ji-Heng Wang; Jing-Ping Du; Ying-Hai Zhang; Xiao-Jun Zhao; Ru-Ying Fan; Zhi-Hong Wang; Zi-Tao Wu; Ying Han
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

Review 2.  Potential roles for prions and protein-only inheritance in cancer.

Authors:  H Antony; A P Wiegmans; M Q Wei; Y O Chernoff; K K Khanna; A L Munn
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

3.  Glycosylphosphatidylinositol Anchor Modification Machinery Deficiency Is Responsible for the Formation of Pro-Prion Protein (PrP) in BxPC-3 Protein and Increases Cancer Cell Motility.

Authors:  Liheng Yang; Zhenxing Gao; Lipeng Hu; Guiru Wu; Xiaowen Yang; Lihua Zhang; Ying Zhu; Boon-Seng Wong; Wei Xin; Man-Sun Sy; Chaoyang Li
Journal:  J Biol Chem       Date:  2015-12-18       Impact factor: 5.157

4.  Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis.

Authors:  Cornelius Kwang-Lee Chieng; Yee-How Say
Journal:  Tumour Biol       Date:  2015-05-17

5.  Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function.

Authors:  David T S Lin; Julie Jodoin; Michaël Baril; Cynthia G Goodyer; Andréa C Leblanc
Journal:  Biochim Biophys Acta       Date:  2008-06-06

6.  The cellular form of the prion protein is involved in controlling cell cycle dynamics, self-renewal, and the fate of human embryonic stem cell differentiation.

Authors:  Young Jin Lee; Ilia V Baskakov
Journal:  J Neurochem       Date:  2012-09-03       Impact factor: 5.372

7.  Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.

Authors:  Le Quang Thao; Hyeong Jun Byeon; Changkyu Lee; Seunghyun Lee; Eun Seong Lee; Yeon Woong Choi; Han-Gon Choi; Eun-Seok Park; Kang Choon Lee; Yu Seok Youn
Journal:  Pharm Res       Date:  2015-11-02       Impact factor: 4.200

8.  Prion protein binding to HOP modulates the migration and invasion of colorectal cancer cells.

Authors:  Tonielli Cristina Sousa de Lacerda; Bruno Costa-Silva; Fernanda Salgueiredo Giudice; Marcos Vinicios Salles Dias; Gabriela Pintar de Oliveira; Bianca Luise Teixeira; Tiago Goss Dos Santos; Vilma Regina Martins
Journal:  Clin Exp Metastasis       Date:  2016-04-25       Impact factor: 5.150

9.  Helix 3 is necessary and sufficient for prion protein's anti-Bax function.

Authors:  Stéphanie Laroche-Pierre; Julie Jodoin; Andréa C LeBlanc
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

10.  Loss of anti-Bax function in Gerstmann-Sträussler-Scheinker syndrome-associated prion protein mutants.

Authors:  Julie Jodoin; Micheal Misiewicz; Priya Makhijani; Paresa N Giannopoulos; Jennifer Hammond; Cynthia G Goodyer; Andréa C LeBlanc
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.